按下ENTER到主內容區
:::

Adult Publicly Funded Pneumococcal Vaccination Upgraded: One Dose of 20-Valent Vaccine Provides Full Protection

From mid January the publicly funded pneumococcal vaccination policy for adults will be upgraded(Photo Aflo Images)
From mid January the publicly funded pneumococcal vaccination policy for adults will be upgraded(Photo Aflo Images)

To reduce the risk of severe illness and death caused by pneumococcal infection in adults, the government has upgraded the publicly funded adult pneumococcal vaccination policy starting in mid-January. The new policy replaces the previous two-dose regimen of the 13-valent and 23-valent vaccines with a single dose of the 20-valent vaccine, allowing eligible individuals to obtain complete immune protection with just one shot.

The Centers for Disease Control, Ministry of Health and Welfare stated that the first phase of eligibility includes adults aged 65 and above, Indigenous people aged 55 to 64, and high-risk individuals aged 19 to 64 for invasive pneumococcal disease (IPD). An estimated 2.45 million people qualify. Those who have never received a pneumococcal vaccine, have only received the 23-valent vaccine more than one year ago, or are high-risk individuals meeting the required vaccination intervals may receive one dose at approximately 2,800 contracted medical institutions nationwide.

The CDC noted that individuals who have already completed vaccination with the 13-valent (or 15-valent) and 23-valent vaccines, or have received the 20-valent vaccine, do not need additional doses. Surveillance data show that IPD cases last year were highest among those aged 65 and above. Eligible individuals are encouraged to receive vaccination promptly. The pneumococcal vaccine may be administered at the same time as influenza and COVID-19 vaccines at different injection sites. Further information is available on the CDC and local health bureau websites.

Popular News

回到頁首
Loading